# VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

> **NCT07629089** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Megan Mantica** · enrollment: 24 (estimated)

## Conditions studied

- Brain Cancer

## Interventions

- **DRUG:** Vorasidenib
- **DRUG:** Lomustine

## Key facts

- **NCT ID:** NCT07629089
- **Lead sponsor:** Megan Mantica
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2030-06-30
- **Final completion:** 2035-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629089, "VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07629089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*